CN101474191A - Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease - Google Patents
Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN101474191A CN101474191A CNA2009100009109A CN200910000910A CN101474191A CN 101474191 A CN101474191 A CN 101474191A CN A2009100009109 A CNA2009100009109 A CN A2009100009109A CN 200910000910 A CN200910000910 A CN 200910000910A CN 101474191 A CN101474191 A CN 101474191A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- active component
- ciclesonide
- teluo
- indenes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 17
- 208000006673 asthma Diseases 0.000 title claims abstract description 17
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims abstract description 31
- 229960003728 ciclesonide Drugs 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 150000002469 indenes Chemical class 0.000 claims description 34
- 238000002156 mixing Methods 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 17
- 229940098458 powder spray Drugs 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000000443 aerosol Substances 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003376 silicon Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000002398 materia medica Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract 4
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 abstract 2
- 229960004078 indacaterol Drugs 0.000 abstract 2
- 230000004199 lung function Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 8
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- -1 electuary Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating asthma and chronic obstructive pulmonary diseases (COPD) which contains the following mixed substances: a first active ingredient indacaterol, or pharmaceutically acceptable salt or solvate thereof, or solvate of the salt; and a second active ingredient ciclesonide; wherein, the mol ratio of the first active ingredient to the second active ingredient is 1:15 to 10:1. The composition is applied to treating asthma, chronic obstructive pulmonary diseases, etc. When the lung function is compared with a base value, the ciclesonide and the indacaterol after being combined to treat has more obvious curative effect than any one to treat. The composition is convenient to take, improves compliance of patients, and obviously improves life quality of patients.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of pharmaceutical composition for the treatment of asthma and chronic obstructive pulmonary disease.
Background technology
Bronchial asthma (bronchial asthma, be called for short asthma) is by the various kinds of cell chronic airway inflammation that participates in of mastocyte, eosinophilic granulocyte and T lymphocyte particularly; This kind inflammation can cause repeatedly symptoms such as the panting of outbreak, tachypnea, uncomfortable in chest and/or cough in the susceptible person, how to take place at night or morning; This type of symptom is often limited with extensive and changeable exhalation flow rate, but natural remission or alleviate through treatment partly; This kind symptom also increases multiple stimulating factor reactivity with air flue.
Chronic obstructive pulmonary disease (Chronic Obstructive Pulmonary Disease, COPD) be a kind of PD, comprise a series of symptoms such as chronic cough, expectoration, exertional dyspnea and tangible reversible or irreversible carrying out property of air-flow minimizing.Generally popular or significantly increase in industrialized country.Cause in the dead disease in the present whole world, COPD arranges the 4th, predicts the year two thousand twenty, and the financial burden that global range endogenous cause of ill COPD is caused will be discharged to the 5th.
The imbedibility glucocorticoid improves patient's pulmonary function and reduces the disease symptoms deterioration rate because of effectively controlling airway inflammation, by a clinical line and the medication of the most effective long term maintenance therapy that is known as the persistence Asthma Population.Ciclesonide is new suction 17-hydroxy-11-dehydrocorticosterone, has its treatment asthma safety and effective of novel and excellent kinetics character and clinical research confirmation.
Indenes Da Teluo is new long-acting beta
2Receptor stimulating agent, clinical trial shows: indenes Da Teluo takes bronchodilatation is reached more than the 24h every day, and its diastole bronchus time ratio salmaterol and formoterol are long; Onset is faster than salmaterol.
The independent application of said two devices all can be treated bronchial asthma.We are through discovering that the applied in any combination of indenes Da Teluo and ciclesonide has good complementary cooperative effect, can better be used for the treatment of asthma and COPD patient.
Summary of the invention
The object of the present invention is to provide that a kind of to have produce effects fast, treatment asthma easy to use and chronic obstructive pulmonary disease (COPD) pharmaceutical composition.
Another object of the present invention is to provide preparation of drug combination method of the present invention.
Pharmaceutical composition of the present invention comprises following two kinds of active component:
(1) first kind of active component indenes Da Teluo, or its pharmaceutically acceptable salt or solvate, or the solvate of this salt;
(2) second kinds of active component ciclesonides;
Wherein, the weight ratio of above-mentioned first kind of active component and second kind of active component is
12-200：10-320μg
Preferred weight ratio is:
25-100：40-160μg
The most preferred weight ratio of the present invention gets through screening:
50：80μg
It is single dose that above-mentioned prescription composition can be made into pharmaceutical preparation, maximum one day secondary of medication number of times.
Ciclesonide is a kind of glucocorticoid with efficient local anti-inflammatory effect, can strengthen the stability of endotheliocyte, smooth muscle cell and lysosome membrane, suppress immunoreation, it is synthetic to reduce antibody, make the release minimizing of allergy active mediums such as histamine, the active reduction, and can alleviate antigen-antibody in conjunction with the time enzymatic processes that excites, suppress the synthetic of bronchoconstriction material and discharge, thereby alleviate the contractile response of smooth muscle.
Indenes Da Teluo is a kind of new long-acting beta 2 receptor stimulating agents, and indenes Da Teluo takes bronchodilatation is reached more than the 24h every day, and its diastole bronchus time ratio salmaterol and formoterol are long; Onset is faster than salmaterol.In addition under static state, the onset time of indenes Da Teluo significantly is shorter than formoterol, and this has just remedied the slower shortcoming of ciclesonide onset, the optional acute asthma etc. that acts on of said composition.In addition, compare the bronchus relexation that indenes Da Teluo can the fugitive beta 2 receptor agonist of antagonism with salmaterol.
Compositions of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: meglumine, mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, ethanol, sucralose, citric acid, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β-cyclodextrin, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate, essence etc., preferably especially select lactose and monohydrate thereof for use, the carrier consumption is preferably 60 μ g-15mg/ agent, more preferably 80 μ g6mg/ agent.
The most preferred prescription of pharmaceutical composition of the present invention in an embodiment.
Pharmaceutical composition of the present invention, its medicine type can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, injection, suppository, cream, spray, drop, patch.
Preferred dosage form is as follows: active component of the present invention can be made powder spray, and preferred dosage form is micronized granule.The imbedibility granule can make the specific position of being distributed in of medicine orientation, and this just is fit to the next directed effect that reaches pulmonary administration of combination that we design two kinds of active component very much.Compare with common administering mode, pulmonary's amount of absorbing the drug significantly increases.Pharmaceutical composition of the present invention can also be made dosage forms such as spray or aerosol.
Preparation of drug combination method of the present invention, its concrete steps are as follows:
At ambient temperature, get ciclesonide, indenes Da Teluo mixing is pulverized; Get dry back lactose and pulverize,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.The present invention can also make dosage forms such as spray, aerosol as required.
Other preferred manufacturing procedure of the present invention in an embodiment.
Among the present invention to the research repeatedly of the pharmacology aspect of first active component and second active component, its result shows that the combination that the compositions of indenes Da Teluo and ciclesonide has a broad compares scope, when being used for the treatment of the patient of asthma and COPD, compare during with first active component of independent application or second active component, composition of active components of the present invention provides better effect.Dosage of the present invention is accurate, and curative effect lasting time is long, and resultant effect is good, instant effect, and safety is good, and good stability is quality controllable, and is easy to use, and low price is fit to large-scale production.
The specific embodiment
To further illustrate the present invention in following examples, these embodiment only are used to the present invention is described and to the present invention without limits.
Embodiment 1, powder spray
At ambient temperature, get 12kg indenes Da Teluo, the 20kg ciclesonide, mixing is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 2, powder spray
At ambient temperature, get 1.2kg indenes Da Teluo, the 32kg ciclesonide, mixing is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 3, powder spray
At ambient temperature, get 20kg indenes Da Teluo, the 2kg ciclesonide, mixing is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 4, spray
At ambient temperature, get 25kg indenes Da Teluo, other gets the 40kg ciclesonide and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 5, spray
At ambient temperature, get 2.5kg indenes Da Teluo, other gets the 16kg ciclesonide and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 6, spray
At ambient temperature, get 10kg indenes Da Teluo, other gets the 4kg ciclesonide and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 7, spray
At ambient temperature, get 10kg indenes Da Teluo, other gets the 16kg ciclesonide and adds mixing dosage in the solvent, and spray is made in fill.50：80μg
Embodiment 8, powder spray
At ambient temperature, get 5kg indenes Da Teluo, the 8kg ciclesonide, mixing is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 9, spray
At ambient temperature, get 1kg indenes Da Teluo, other gets the 1.6kg ciclesonide and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 10, aerosol
Get 5kg indenes Da Teluo micropowder, other gets 8kg ciclesonide micropowder and puts in the vacuum drying oven and dry, and it is standby to be cooled to room temperature.Temperature is controlled at below 15 ℃, will dry material and add tween and place stainless steel cask to add the propellant mixing, stirs, and aerosol is made in fill.
Embodiment 11
At ambient temperature, get the 20kg ciclesonide, 25kg indenes Da Teluo mixing is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 12
At ambient temperature, get the 15kg ciclesonide, other gets 20kg indenes Da Teluo mixing, is crushed to mean diameter 1-5 μ m; Get dry back lactose and be crushed to mean diameter 1-5 μ m,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
Embodiment 13
At ambient temperature, get the 20kg ciclesonide, other gets 18kg indenes Da Teluo and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 14
At ambient temperature, get the 10kg ciclesonide, other gets 24kg indenes Da Teluo and adds mixing dosage in the solvent, and spray is made in fill.
Embodiment 15
Get 12kg ciclesonide micropowder, other gets 36kg indenes Da Teluo micropowder and puts in the vacuum drying oven and dry, and it is standby to be cooled to room temperature.Temperature is controlled at below 15 ℃, will dry material and add tween and place stainless steel cask to add the propellant mixing, stirs, and aerosol is made in fill.
Embodiment 16
Get 25kg ciclesonide micropowder, other gets 12kg indenes Da Teluo micropowder and puts in the vacuum drying oven and dry, and it is standby to be cooled to room temperature.Temperature is controlled at below 15 ℃, will dry material and add tween and place stainless steel cask to add the propellant mixing, stirs, and aerosol is made in fill.
Embodiment 17,
Test 1. physical data:
1.1, select COPD stable phase patient, be divided into approximately equalised 3 groups of number---treatment group and matched group 1 and 2 then at random, every index of 3 groups of patients more all has comparability before treatment, the treatment group is a pharmaceutical composition of the present invention, 1 administration indenes of matched group Da Teluo, 2 administration ciclesonides of matched group, each 1 inhales, every day 2 times, the time is 6 months.
1.2, research method: three groups are adopted following method to treat respectively: 30 examples are organized in treatment, and the patient goes into the group back and uses ciclesonide/indenes Da Teluo powder spray (every suction 80 μ g/50 μ g) of making by embodiment each 1 and inhale every day 1 time.Matched group 1 and 2 each 30 example are used indenes Da Teluo powder spray (every suction 50 μ g), ciclesonide powder spray (every suction 80 μ g), and each 1 inhales every day 1 time.30min respectively surveys PEF3 time before and after sucking, and gets maximum PEF value, calculates the improvement rate of PEF.
In one week of the course of treatment, finish back check FEV
1% compares.
Criterion of therapeutical effect: PEF improvement rate: outstanding:〉36%, good: 26% ~ 35%, general 16% ~ 25%, relatively poor:＜15%.FEV
1% improves degree: outstanding:〉26%, good: 16% ~ 25%, general: 0 ~ 15%.
1.3 experimental data and result:
1. respectively organize the PEF situation of change and see Table 1
Table 1 respectively organize PEF improvement rate relatively (example, %)
| Group | Outstanding | Well | Generally | Relatively poor |
| Matched group 1 (n=30) | 7(23.3％) | 13(43.3％) | 6(20％) | 4(13.3％) |
| Matched group 2 (n=30) | 6(20％) | 12(40％) | 5(16.7％) | 7(23.3％) |
| Treatment group (n=30) | 10(33.3％) | 14(46.7％) | 4(13.3％) | 2(6.7％) |
Three groups of PEF improvement rates compare, and the outstanding and good rate of treatment group is 80.0%, is higher than matched group.
2. respectively organize FEV
1The % situation of change sees Table 2
Table 2 FEV before and after the course of treatment
1The comparison of % increase situation (example, %)
| Group | Outstanding | Well | Generally |
| Matched group 1 (n=30) | 9(30.0％) | 11(36.7％) | 10(33.3％) |
| Matched group 2 (n=30) | 8(26.7％) | 10(33.3％) | 12(40％) |
| Treatment group (n=30) | 12(40％) | 13(43.3％) | 5(16.7％) |
Three groups of FEV
1% all has increase, but the outstanding and good rate of treatment group is 83.3%, is higher than matched group.
3. respectively organize the situation of clinical symptoms change
Panting behind matched group 1 and the 2 suction 5-10min begins to alleviate, and finishes symptoms such as back cough, expectoration the course of treatment and is clearly better.The beginning of panting behind the treatment group suction 5-10min is obviously alleviated, and cough after finishing the course of treatment, expectoration symptom and the every index of quality of life all are clearly better.Two groups of patients all do not have untoward reaction such as obvious xerostomia, cardiopalmus and heart rate and tachypnea during treating.
By top data and analysis, use in conjunction indenes Da Teluo and ciclesonide are the ideal measure of quick relieving asthma and the various acute attacks of COPD, severe asthma is solved bronchospasm especially fast, improves anoxybiotic critical treatment means, and easy and simple to handle, safe and reliable.
Claims (10)
1, a kind of treat asthma and chronic obstructive pulmonary disease pharmaceutical composition, it is characterized in that, comprise following two kinds of active component: wherein first kind of active component is selected from: indenes Da Teluo, or its pharmaceutically acceptable salt or solvate, or the solvate of this salt; Second kind of active component ciclesonide.
2, the described pharmaceutical composition of claim 1 is characterized in that, the weight ratio of described first kind of active component and second kind of active component is 12-200:10-320 μ g.
3, the described pharmaceutical composition of claim 1 is characterized in that, the weight ratio of described first kind of active component and second kind of active component is 25-100: 40-160 μ g.
4, the described pharmaceutical composition of claim 1 is characterized in that, the weight ratio of described first kind of active component and second kind of active component is 50: 80 μ g.
5, the described pharmaceutical composition of claim 1, it is characterized in that, when being prepared into pharmaceutical preparation, optionally add acceptable carrier on the suitable materia medica, wherein carrier is selected from: meglumine, mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, ethanol, sucralose, citric acid, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β-cyclodextrin, the phospholipid material, Kaolin, Talcum, calcium stearate, magnesium stearate, essence, lactose and monohydrate thereof.
6, the described pharmaceutical composition of claim 1 is characterized in that, its medicine type is any pharmaceutically useful dosage form.
7, the described pharmaceutical composition of claim 1 is characterized in that, its medicine type is: powder spray, spray or aerosol.
8, the described pharmaceutical composition of claim 1 is characterized in that preparation method is as follows: at ambient temperature, get ciclesonide, indenes Da Teluo mixing is pulverized; Get dry back lactose and pulverize,, this powder is filled into makes powder spray in the filling machine then with above-mentioned powder mixing.
9, the described pharmaceutical composition of claim 1 is characterized in that preparation method is as follows: at ambient temperature, get ciclesonide and indenes Da Teluo and add mixing dosage in the solvent, spray is made in fill.
10, the described pharmaceutical composition of claim 1 is characterized in that preparation method is as follows: get ciclesonide micropowder and indenes Da Teluo micropowder and put in the vacuum drying oven and dry, it is standby to be cooled to room temperature; Temperature is controlled at below 15 ℃, will dry material and add tween and place stainless steel cask to add the propellant mixing, stirs, and aerosol is made in fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100009109A CN101474191B (en) | 2009-01-21 | 2009-01-21 | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100009109A CN101474191B (en) | 2009-01-21 | 2009-01-21 | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101474191A true CN101474191A (en) | 2009-07-08 |
| CN101474191B CN101474191B (en) | 2011-03-23 |
Family
ID=40835038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100009109A Expired - Fee Related CN101474191B (en) | 2009-01-21 | 2009-01-21 | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101474191B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266344A (en) * | 2010-06-04 | 2011-12-07 | 北京阜康仁生物制药科技有限公司 | Pharmaceutical composition used for treating respiration disorders |
| WO2012049444A1 (en) * | 2010-10-12 | 2012-04-19 | Cipla Limited | Pharmaceutical composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| AU2006329042B2 (en) * | 2005-12-21 | 2012-02-02 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| CN101249093A (en) * | 2008-03-19 | 2008-08-27 | 李虎山 | Combination for curing chronic obstructive disease of lung |
-
2009
- 2009-01-21 CN CN2009100009109A patent/CN101474191B/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266344A (en) * | 2010-06-04 | 2011-12-07 | 北京阜康仁生物制药科技有限公司 | Pharmaceutical composition used for treating respiration disorders |
| WO2012049444A1 (en) * | 2010-10-12 | 2012-04-19 | Cipla Limited | Pharmaceutical composition |
| JP2013542940A (en) * | 2010-10-12 | 2013-11-28 | シプラ・リミテッド | Pharmaceutical composition |
| US20140147393A1 (en) * | 2010-10-12 | 2014-05-29 | Cipla Limited | Pharmaceutical Composition |
| AU2011315315B2 (en) * | 2010-10-12 | 2016-08-18 | Cipla Limited | Pharmaceutical composition |
| JP2017039746A (en) * | 2010-10-12 | 2017-02-23 | シプラ・リミテッド | Pharmaceutical composition |
| RU2642624C2 (en) * | 2010-10-12 | 2018-01-25 | Сипла Лимитед | Pharmaceutical composition |
| CN107998109A (en) * | 2010-10-12 | 2018-05-08 | 西普拉有限公司 | Pharmaceutical composition |
| US10179139B2 (en) | 2010-10-12 | 2019-01-15 | Cipla Limited | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101474191B (en) | 2011-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210244705A1 (en) | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection | |
| JP7492548B2 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| CN101474191B (en) | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease | |
| CN101264092A (en) | Compound preparations with ciclesonide and formoterol as active component and preparation and application thereof | |
| CN103989695B (en) | A kind of pharmaceutical composition and application thereof treating bronchial asthma | |
| CN105640924A (en) | Alendronate sodium powder inhalation used for respiratory drug delivery and preparation method and application thereof | |
| CN103860525B (en) | A kind of capsule type inhalation aerosol powder containing effective ingredient ambrisentan and preparation technology thereof | |
| CN111481550A (en) | Pharmaceutical formulation containing tiotropium bromide and arformoterol | |
| CN101849928A (en) | Inhalation preparation for treating asthma, preparation method and application thereof | |
| CN104758294A (en) | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof | |
| CN101069688A (en) | Medicine composition containing theocin-like medicines and vitamin K | |
| CN101842102A (en) | DHEAS inhalation compositions | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN104224819B (en) | A kind of naringin and levo-cetirizine hydrochloride pharmaceutical composition and preparation thereof | |
| CN101023953A (en) | Composition for treating bronchia asthma | |
| CN113350325A (en) | Application of dianthrone compound in preparation of antitumor drugs | |
| CN106511277A (en) | Polaprezinc granule and preparation method thereof | |
| CN102258504A (en) | Compound salbutamol sulfate and ambroxol hydrochloride inhalation solution | |
| CN113456619A (en) | Dipyridamole inhalant and preparation method thereof | |
| CN114344380A (en) | Asthma-relieving aerosol inhalation solution preparation and preparation method thereof | |
| CN103919788A (en) | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease | |
| CN102727467A (en) | Dry powder inhalant of interferon alpha | |
| CN114699492B (en) | Application of lung cough and cyclophosphamide combined medicine in preparation of product for treating breast cancer | |
| CN101797258A (en) | Medicine composition containing oral glucocorticoid and oral bronchodilator | |
| CN105288107A (en) | Compound hippophae rhamnoides composition for clearing heat from throat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WEIFANG ZHONGSHI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LI HUSHAN Effective date: 20111024 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 261206 WEIFANG, SHANDONG PROVINCE TO: 261061 WEIFANG, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111024 Address after: 261061 Weifang Shandong hi tech Zone bio pharmaceutical science and Technology Industrial Park Patentee after: Weifang Zhongshi Pharmaceutical Co.,Ltd. Address before: 123 261206 North Sea Road, Fangzi District, Shandong, Weifang Patentee before: Li Hushan |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110323 Termination date: 20210121 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |